Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (SEHK: 6990)
Health Care · Biotechnology · CN
HK$520.50
-3.52% today · +16.5% 1Y
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (SEHK: 6990) operates in the Biotechnology industry within the Health Care sector. The company is valued at $15.85B and employs 2,045 people.
Over the last twelve months the share price has gained 16.5%, trading between 339.60 and 581.00.
Tweenvest scores Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. across four factors: quality 47/100, value 56/100. Its strongest factor is value.
6990 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $15.85B
- Revenue (TTM)
- $294.22M
- P/E
- —
- EPS
- -1.66
- Dividend yield
- —
- Beta (5Y)
- -0.02
- 52-week high
- HK$581.00
- 52-week low
- HK$339.60
- Avg volume (3M)
- —
- Shares outstanding
- 239.02M
- Employees
- 2,045
- Next earnings
- —
About Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally. The company’s product pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors; Trastuzumab botidotin, a monotherapy to treat advanced HER2+ solid tumors; SKB315, a novel CLDN18.2 ADC targeting advanced solid tumors; SKB410/MK-3120, a novel Nectin-4 ADC targeting advanced solid tumors; and SKB571/MK-2750, a novel bsADC primarily targeting various solid tumors, such as LC and CRC. The company also develops SKB518, SKB535/MK-6204 and SKB445, which are novel ADC drugs with potential FIC targets; SKB500 and SKB501, which are novel ADC drugs with verified targets but differentiated payload-linker strategies; SKB107, an RDC targeting tumor bone metastases; Tagitanlimab, PD-L1 mAb for its immunotherapy franchise; Cetuximab N01, a recombinant EGFR human-mouse chimeric mAb; A400, a novel selective RET inhibitor; and A296, a novel small molecule STING agonist. It has license and collaboration arrangements with Merck Sharp & Dohme LLC; Harbour BioMed Therapeutics Limited; Windward Bio AG; and Ellipses Pharma Limited. The company has a strategic partnership with Crescent Biopharma, Inc. The company was incorporated in 2016 and is headquartered in Chengdu, the People’s Republic of China. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.
- ISIN
- CNE1000062J1
- Founded
- 2016
- Listed since
- Jul 11, 2023
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.08 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $442.95 | -0.20% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.37 | -0.26% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $545.46 | -0.39% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $826.01 | -0.30% |
| argenx SEENXTBR: ARGX | $63.06B | €872.20 | +0.93% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $144.03 | +3.70% |
Figures last refreshed Aug 18, 2026.